Go Deep
Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,008 | 20.9 | 3.92 | 0.12 | 13,758.05 |
| Oct 2026 | 19,991 | 20.7 | 3.89 | 0.12 | 13,534.84 |
| Oct 2026 | 20,308 | 19.8 | 3.72 | 0.12 | 12,868.93 |
| Oct 2026 | 20,276 | 19.9 | 3.74 | 0.12 | 12,904.31 |
| Oct 2026 | 20,234 | 20.0 | 3.77 | 0.12 | 13,004.91 |
| Oct 2026 | 20,285 | 19.9 | 3.73 | 0.12 | 12,853.77 |
| Oct 2026 | 20,233 | 20.1 | 3.77 | 0.12 | 12,987.95 |
| Oct 2026 | 20,028 | 20.8 | 3.91 | 0.12 | 13,463.93 |
| Oct 2026 | 20,056 | 20.7 | 3.89 | 0.12 | 13,365.41 |
| Oct 2026 | 19,975 | 21.0 | 3.94 | 0.12 | 13,525.26 |
Neurocrine Biosciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 959,000,000.0 | 814,500,000.0 | 805,500,000.0 | 794,900,000.0 |
| Net Profit | 144,400,000.0 | 197,900,000.0 | 153,700,000.0 | 209,500,000.0 |
| EPS | 1.4 | 2.0 | 1.5 | 2.1 |
Neurocrine Biosciences, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 2,860,500,000.0 | 2,355,300,000.0 | 1,887,100,000.0 | 1,488,700,000.0 | — |
| Net Profit | 478,600,000.0 | 341,300,000.0 | 249,700,000.0 | 154,500,000.0 | — |
| EPS | 4.8 | 3.4 | 2.6 | 1.6 | — |
Neurocrine Biosciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 4,631,500,000.0 | 3,718,700,000.0 | 3,251,400,000.0 | 2,368,700,000.0 | — |
| Total Liabilities | 1,378,400,000.0 | 1,129,000,000.0 | 1,019,400,000.0 | 660,900,000.0 | — |
| Total Equity | 3,253,100,000.0 | 2,589,700,000.0 | 2,232,000,000.0 | 1,707,800,000.0 | — |
Owes vs Owns
Neurocrine Biosciences, Inc. owed $0.31 for every $1 it owned in Jun 2026, up from $0.28 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.31× | 0.30× | 0.30× | 0.31× | 0.28× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Neurocrine Biosciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 32.0%Receivables 14.8%Inventory 1.5%Fixed assets (tangible) 11.8%Long-term investments 25.6%Other assets 14.4%
How it's funded — Dec 2025
Long-term debt 9.0%Payables 2.3%Other liabilities 18.5%Shareholders' equity 70.2%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1,480.4 | 1,076.1 | 1,031.6 | 989.3 |
| Receivables | 686.8 | 479.1 | 439.3 | 350.0 |
| Inventory | 69.0 | 57.4 | 38.3 | 35.1 |
| Fixed assets (tangible) | 545.2 | 592.0 | 347.3 | 145.6 |
| Intangible assets | 0.0 | 36.5 | 35.5 | 37.2 |
| Long-term investments | 1,183.8 | 864.3 | 849.4 | 401.5 |
| Other assets | 666.3 | 613.3 | 510.0 | 410.0 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 170.1 | 169.4 |
| Long-term debt | 415.3 | 455.1 | 258.3 | 93.5 |
| Payables | 104.9 | 99.9 | 133.3 | 67.3 |
| Other liabilities | 858.2 | 574.0 | 457.7 | 330.7 |
| Shareholders' equity | 3,253.1 | 2,589.7 | 2,232.0 | 1,707.8 |
| Net tangible assets | 3,253.1 | 2,589.7 | 2,196.5 | 1,670.6 |
Neurocrine Biosciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 782,700,000.0 | 595,400,000.0 | 389,900,000.0 | 339,400,000.0 | — |
| Investing Activities | -264,400,000.0 | -126,800,000.0 | -467,100,000.0 | -177,100,000.0 | — |
| Financing Activities | -38,300,000.0 | -486,700,000.0 | 65,300,000.0 | -234,300,000.0 | — |